Pharmaceutical representatives were investigated by well-known pharmaceutical companies in response.

The drug companies involved said they had worked for the company but had left at the end of 2018 and had always focused on compliance promotion, strictly complying with all relevant laws and regulations, and following business ethics standardsThe Company will continue to adhere resolutely to compliance operations and will always take any violations or violations of company values into a zero-tolerance mannerAccording to Seiberan previously reported that the cause of the incident is a well-known pharmaceutical company's oncology product line of two representatives in the clinic to shoot a doctor's prescription, was seen by the head nurse and the police to take him away, and then further involved with the district managerIn this case, a domestic pharmaceutical company executive told Saberlan today, pharmaceutical representatives have compliance problems, it is difficult to completely avoid, just as although there is a law, but there are always people who break the law, said not to run a red light, but there will be people to runAccording to his understanding, at present, basically every pharmaceutical company has a special compliance officer, will also highly emphasize the concept of compliance, for the incoming staff, pharmaceutical companies will carry out the corresponding compliance education, compliance training, pharmaceutical representatives are also required to sign the corresponding staff manual, committed to their own work in accordance with the corresponding norms, and for non-compliance behavior, the general corporate posture is once the non-compliance situation, on the resolute investigation, medical representative non-compliance is certainly to bear the corresponding responsibilityThe executives further said that compliance requirements are not just for the conduct of individual pharmaceutical representatives, but also related to drug registration, corporate law, corporate marketing, etcMoreover, in a broad sense, compliance is not only regulated by pharmaceutical enterprises, compliance requirements are not unique to pharmaceutical enterprises, all enterprise subjects need to comply with anti-commercial bribery law and other laws and norms of the requirementsIt is important to note that the implementation of the relevant departments has been strengthened recently in response to non-compliance in the field of pharmaceutical purchase and saleTo rectify the purchase and sale of medicine, multi-party policy of the above-mentioned pharmaceutical representatives compliance behavior is essentially involved in the purchase and sale of medicineRecently, the relevant departments for the sale of gold, pharmaceutical commercial bribery and other acts, began to introduce relevant norms intensivelySeiber Blue special author Code Wanxuan on the Seiber Blue analysis pointed out that the recent multi-sector has issued a special governance document, in general feel that the above-mentioned documents strengthen the supervision of pharmaceutical representatives, pharmaceutical companies, both pay attention to macro-regulation, but also emphasize micro-strikesFurther analysis of the code Wanxuan pointed out that the governance of the field of pharmaceutical purchase and sale is accompanied by a series of reform measures in various fields of the three medical linkage, the aim is to deepen the new medical reform a "severe" "clean air" environmentThis kind of policy provisions and law enforcement disposal, in the role of play shows the basic, long-term, flexible characteristics, the state in the field of medicine to strengthen the construction of the rule of law, regulate the pharmaceutical market behavior of some practices for legislation, law enforcement provides a referenceOn the recent documents, Beijing Shengshi Kanglai Chinese medicine marketing planning company chairman Shen Yong said to Sei-Lan, in his view, mainly divided into pharmaceutical representatives, enterprises, hospitals on several levels of the pharmaceutical enterprises to regulate the purchase and sale of behaviorEarlier, the State Drug Administration issued a new version of the drug generation management measures for the draft of the draft stressed - pharmaceutical representatives may not undertake sales tasks, and specifically to the pharmaceutical representatives may not participate in the statistics of the number of prescriptions of drugs issued by individual doctors, may not directly sell physical drugs, may not collect and process purchase and sale invoices, may not carry out commercial bribery, medical and health institutions set up departments and individuals directly provide donation spending, etc., is from the national level to regulate the pharmaceutical representatives before the drug generation management measures, before the drug generation management measures, The norms for medical representatives are mainly at the hospital, city and provincial levelsOn July 24th, the General Office of the National Health and Care Commission issued the Notice on the Issue of the Special Action Plan for the Construction of the Medical Industry in 2020, which is from the perspective of hospitals and doctors to crack down on the issue of commercial bribery in medicineLast year's fiscal inspection and medical insurance bureau issued "on the establishment of pharmaceutical prices and recruitment credit evaluation system guidance (draft for comments)" is from the perspective of enterprises to regulate the purchase and sale of medicine behaviorPharmaceutical enterprises, pharmaceutical generation how to deal with Shen Yong further pointed out that in the performance pressure and profit driven by the pharmaceutical representatives will inevitably appear non-compliance behavior, then it is necessary to strengthen the punishment of illegal pharmaceutical representatives and further standardize their behavior, in the face of the current compliance situation, Shen Yong suggested that pharmaceutical representatives return to their jobs, without abandoning sales at the same time, do a good job of academic promotionCode Wanxuan further said that the pharmaceutical representative is a specific historical period of human resources, policy tightening is to combat the pharmaceutical representative's irregular, does not meet the needs of the market order violations, rather than completely deny the existence of the work of medical representativesHowever, MrCode also pointed out, "We also have to think about three million medical representatives, is it really too much?" If the legal compliance of its business conduct is effectively regulated, and the medical representatives play a bridge between medical and pharmaceutical, how many medical representatives are needed, is it balanced and adequate?" As for how pharmaceutical companies are coping with increasing compliance pressures, MrCode suggests that companies need to reflect on the rationality and sustainability of old practices in the new competitive environmentThe so-called rationality, that is, compared with output and the corresponding risk, with gold sales how much reasonable? The so-called sustainability, that is, in the face of all aspects of the code control, gold sales are punished, is it still normal for enterprises to bear? At the same time, but also to study the possibility of conversion practices, as far as possible through a compliant and reasonable way to carry out promotional work - for example: bigger and stronger academic promotion, to make features and effectivenessCombined with the needs of clinical development, to help hospital doctors enhance the value of technical servicesProperly forward-looking, stand in the perspective of hospital doctors, to meet external competition